AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02049346
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used.
Trial: NCT02049346
Drug: Methoxy polyethylene glycol-epoetin beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.
Trial: NCT03976050
Drug: HL-085
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
Trial: NCT03096392
Drug: HDV insulin lispro 100 UNT/ML
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
Trial: NCT03096392
Drug: Insulin Lispro 100 UNT/ML
RxNorm normalized name: insulin lispro 100 UNT/ML
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
Trial: NCT00353301
Drug: Erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive single-agent Tarceva, 150 mg/day
Trial: NCT00353301
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
Trial: NCT01166789
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48ug daily taken as 24ug capsules twice per day, in morning and evening.
Trial: NCT03697161
Drug: OV101 (gaboxadol)
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OV101 (gaboxadol)
Trial: NCT03885154
Drug: Valproic Acid (VPA)
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
Trial: NCT03885154
Drug: Dihydroergotamine (DHE)
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
Trial: NCT00003322
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003322
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02253095
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01504516
Drug: Donepezil Hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil Hydrochloride Tablets 10 mg
Trial: NCT01504516
Drug: Aricept
RxNorm normalized name: Aricept
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aricept 10 mg Tablets
Trial: NCT00315952
Drug: Exubera
RxNorm normalized name: EXUBERA
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00361972
Drug: lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg of lansoprazole twice daily for 6 weeks
Trial: NCT06192472
Drug: 1% Sodium Tetradecyl Sulphate
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% Sodium Tetradecyl Sulphate
Trial: NCT06192472
Drug: 3% Sodium Tetradecyl Sulphate
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% Sodium Tetradecyl Sulphate
Trial: NCT06192472
Drug: 0.5% Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% Polidocanol
Trial: NCT00004744
Drug: immune globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03012828
Drug: Moxidectin
RxNorm normalized name: moxidectin
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin is a broad spectrum macrocyclic lactone endectocide
Trial: NCT00283101
Drug: SGN-40 (anti-huCD40 mAb)
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
Trial: NCT03768089
Drug: Placebo (matched to VX-121 suspension)
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-121 suspension for oral administration.
Trial: NCT03768089
Drug: VX-121 (Suspension)
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT03768089
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT03768089
Drug: VX-121 (Tablet)
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT03768089
Drug: Placebo (matched to VX-121 tablet)
RxNorm normalized name: nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-121 tablet for oral administration.
Trial: NCT00817765
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
Trial: NCT00817765
Drug: Fosamprenavir
RxNorm normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fosamprenavir tablet 700mg; 1 tablet BID for 10 days
Trial: NCT00817765
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 100mg capsule; 1 capsule BID for 10 days
Trial: NCT00480831
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00480831
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00480831
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00881530
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 high dose once daily
Trial: NCT00881530
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open label comparator
Trial: NCT00881530
Drug: BI 10773
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 10773 low dose once daily
Trial: NCT00881530
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open label comparator
Trial: NCT02103062
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02705612
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02705612
Drug: nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003776
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003776
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003776
Drug: trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00763256
Drug: Triclosan, Fluoride
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
Trial: NCT00763256
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
Trial: NCT03686930
Drug: Cohort 1 - FP-045 oral solution
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Trial: NCT03686930
Drug: Cohort 2 - FP-045 oral solution
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Trial: NCT03686930
Drug: Cohort 3 - FP-045 oral solution
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
Trial: NCT02659527
Drug: 68Ga- PSMA-HBED-CC
RxNorm normalized name: (68Ga)Psma-hbed-CC
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
Trial: NCT01565408
Drug: NNC0114-0006
RxNorm normalized name: NNC0114-0006
DrugBank: NNC0114-0006 (DB18361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
Trial: NCT01123031
Drug: lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
Trial: NCT01123031
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
Trial: NCT01838460
Drug: sublingual nicotine tablets
RxNorm normalized name: nicotine Sublingual Tablet
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 mg = 3 tablets
Trial: NCT04364815
Drug: Hydroxychloroquine plus standard preventive measures
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine and standard preventive measures
Trial: NCT04048889
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
Trial: NCT04048889
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
Trial: NCT04048889
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
Trial: NCT00384215
Drug: insulin glargine [rDNA origin] injection
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01637584
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
Trial: NCT03536325
Drug: Guselkumab Dose 1
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Dose 1 of guselkumab on Day 1.
Trial: NCT03536325
Drug: Guselkumab Dose 2
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Dose 2 of guselkumab on Day 1.
Trial: NCT03536325
Drug: Guselkumab Dose 3
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Dose 3 of guselkumab on Day 1.
Trial: NCT00517010
Drug: Proton beam irradiation and ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
Trial: NCT02030769
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
Trial: NCT01183429
Drug: 3F8 and 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. \*High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
Trial: NCT01501890
Drug: dihydroxyprogesterone caproate
RxNorm normalized name: Hydroxyprogesterone Caproate
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250mg once a week by intramuscular administration
Trial: NCT04149171
Drug: with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
Trial: NCT01222819
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mcg/kg (rounded to 300 mcg or 480 mcg)
Trial: NCT04342676
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: vectibex in stage iv
Trial: NCT03672851
Drug: anti-CD123 CAR-T treatment
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
Trial: NCT00000553
Drug: niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02534883
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be place vaginally
Trial: NCT01223339
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
Trial: NCT01223339
Drug: Ertugliflozin
RxNorm normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
Trial: NCT00418704
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tarceva (150 mg) is a pill you take once a day -- every day
Trial: NCT00418704
Drug: taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
Trial: NCT02599311
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolterodine tartrate can improve patients' LUTS.
Trial: NCT00731861
Drug: Paclitaxel plus PTK787
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY.
Trial: NCT01704508
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03135912
Drug: Terbinafine Hydrochloride
RxNorm normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical terbinafine hydrochloride cream.
Trial: NCT03599778
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX + apatinib's MTD
Trial: NCT00006131
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no